Voyager Therapeutics reported a quarterly loss of $0.47 per share, beating the Zacks Consensus Estimate for a $0.54 loss by $0.07 per share. The result also improved from a loss of $0.53 per share a year ago. This is a modest earnings beat for the biotech company and is likely to have limited but positive stock impact.
Voyager Therapeutics reported a quarterly loss of $0.47 per share, beating the Zacks Consensus Estimate for a $0.54 loss by $0.07 per share. The result also improved from a loss of $0.53 per share a year ago. This is a modest earnings beat for the biotech company and is likely to have limited but positive stock impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
